88 related articles for article (PubMed ID: 1419631)
1. CA-125 is not a useful marker in metastatic breast cancer.
Seckl MJ; Rustin GJ; Coombes RC
Br J Cancer; 1992 Nov; 66(5):875-6. PubMed ID: 1419631
[No Abstract] [Full Text] [Related]
2. CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years.
Pizzichetta M; Bogni A; Seregni E; Maffioli L; de Jager E; Costa A; Bombardieri E
Int J Biol Markers; 1992; 7(1):59-60. PubMed ID: 1583349
[No Abstract] [Full Text] [Related]
3. CA-549 serum levels in breast cancer monitoring.
Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
Int J Biol Markers; 1992; 7(4):217-21. PubMed ID: 1491176
[TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
Eur J Cancer; 1992; 28A(4-5):845-50. PubMed ID: 1524905
[TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29.
Correale M; Abbate I; Gargano G; Catino A; Dragone CD; Musci MD; Serio G; Paradiso A; De Lena M
Int J Biol Markers; 1992; 7(1):43-6. PubMed ID: 1583347
[TBL] [Abstract][Full Text] [Related]
6. Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.
Dixon AR; Price MR; Hand CW; Sibley PE; Selby C; Blamey RW
Br J Cancer; 1993 Nov; 68(5):947-9. PubMed ID: 8217608
[TBL] [Abstract][Full Text] [Related]
7. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer.
Locker GJ; Mader RM; Braun J; Sieder AE; Marosi C; Rainer H; Jakesz R; Steger GG
Oncology; 1995; 52(2):140-4. PubMed ID: 7854774
[TBL] [Abstract][Full Text] [Related]
8. CA 549: the theorem of Bayes for obtaining cut-off values.
Blasco R; Rodriguez Cortasa MJ; Barbero EM; Colmenarejo A; Munoz Calvo R
Int J Biol Markers; 1992; 7(4):270. PubMed ID: 1491188
[No Abstract] [Full Text] [Related]
9. Review of clinical studies of CA 27.29 in breast cancer management.
Beveridge RA
Int J Biol Markers; 1999; 14(1):36-9. PubMed ID: 10367248
[TBL] [Abstract][Full Text] [Related]
10. Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (M85/F36) and its comparison with CA 15-3.
Chu TM; Constantine R; Nemoto T
J Clin Lab Anal; 1989; 3(5):267-72. PubMed ID: 2681619
[TBL] [Abstract][Full Text] [Related]
11. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
Bombardieri E; Pizzichetta M; Veronesi P; Seregni E; Bogni A; Maffioli L; Jotti GS; Bassetto MA; Zurrida S; Costa A
Eur J Cancer; 1992; 29A(1):144-6. PubMed ID: 1445733
[TBL] [Abstract][Full Text] [Related]
12. Ceruloplasmin level in women with breast disease. Preliminary results.
Ozyilkan O; Baltali E; Ozyilkan E; Tekuzman G; Kars A; Firat D
Acta Oncol; 1992; 31(8):843-6. PubMed ID: 1290632
[TBL] [Abstract][Full Text] [Related]
13. Experience with CA 15.3 as a tumor marker in breast cancer.
Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
[TBL] [Abstract][Full Text] [Related]
14. [CA-12 tumor marker values in serum following radioimmuno-scintigraphy].
Barrada M; Pateisky N; Schatten C; Philipp K; Sevelda P; Vavra N
Gynakol Rundsch; 1990; 30 Suppl 1():72-3. PubMed ID: 2079306
[No Abstract] [Full Text] [Related]
15. Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer management.
Jensen JL; Maclean GD; Suresh MR; Almeida A; Jette D; Lloyd S; Bodnar D; Krantz M; Longenecker BM
Int J Biol Markers; 1991; 6(1):1-6. PubMed ID: 1856511
[TBL] [Abstract][Full Text] [Related]
16. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
17. Sialyl Tn as a prognostic marker in epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
Br J Cancer; 1992 Nov; 66(5):984-5. PubMed ID: 1419648
[No Abstract] [Full Text] [Related]
18. Elevated serum tumour markers and systemic disease.
van Dalen A
Tumour Biol; 1989; 10(6):330-1. PubMed ID: 2595214
[No Abstract] [Full Text] [Related]
19. Report of BACR workshop on monoclonal antibodies in breast and ovarian cancer, Brasenose College, Oxford March 17-19th 1991.
Leonard RC; Fisken J; Roulston JE
Br J Cancer; 1991 Oct; 64(4):796-7. PubMed ID: 1911231
[No Abstract] [Full Text] [Related]
20. Serum and cytosolic levels of CA549 in breast cancer patients.
Correale M; Abbate I; Dragone CD; Tedone T; Gargano G; Catino A; Paradiso A; Addabbo L; Musci MD; De Lena M
Clin Exp Obstet Gynecol; 1993; 20(4):264-7. PubMed ID: 8281711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
